BillionToOne, Inc. Class A Common Stock (BLLN)vsNatera Inc (NTRA)
BLLN
BillionToOne, Inc. Class A Common Stock
$97.19
-7.08%
HEALTHCARE · Cap: $4.52B
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 605% more annual revenue ($2.50B vs $354.54M). BLLN leads profitability with a 7.0% profit margin vs -9.1%. BLLN earns a higher WallStSmart Score of 40/100 (F).
BLLN
Hold40
out of 100
Grade: F
NTRA
Avoid31
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 83.8% year-over-year
Conservative balance sheet, low leverage
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.8x book value
0.0% earnings growth
ROE of 5.0% — below average capital efficiency
7.0% margin — thin
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth, Debt/Equity. Revenue growth of 83.8% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : BLLN
The primary concerns for BLLN are Price/Book, EPS Growth, Return on Equity. A P/E of 182.2x leaves little room for execution misses.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
BLLN is growing revenue faster at 83.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BLLN scores higher overall (40/100 vs 31/100) and 83.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?